ストックスクリーナーアプリを入手
1.41
3.42%
-0.05
前日終値:
$1.46
開ける：
$1.44
24時間の取引高:
944.52K
Relative Volume:
0.31
時価総額：
$586.50M
収益：
$400.57M
当期純損益:
$9.21M
株価収益率:
35.25
EPS:
0.04
ネットキャッシュフロー:
$146.36M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-12.96%
6か月 パフォーマンス:
-64.93%
1年 パフォーマンス:
-83.81%
1日の値動き範囲:
$1.375
$1.44
1週間の範囲:
$1.37
$1.53
52週間の値動き範囲:
$1.34
$8.64
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
名前
Ironwood Pharmaceuticals Inc
セクター
電話
617-621-7722
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.41 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-09 | 開始されました | Leerink Partners | Market Perform |
| 2024-08-08 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 開始されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Wells Fargo | Overweight |
| 2023-11-09 | 開始されました | Jefferies | Buy |
| 2023-09-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-02 | 開始されました | CapitalOne | Overweight |
| 2022-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-09-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 開始されました | Northland Capital | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | アップグレード | JP Morgan | Underweight → Neutral |
| 2018-11-07 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 開始されました | H.C. Wainwright | Sell |
| 2018-05-09 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2017-07-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 開始されました | Wells Fargo | Outperform |
| 2017-04-07 | 繰り返されました | Mizuho | Buy |
| 2017-02-22 | 繰り返されました | Barclays | Equal Weight |
| 2016-11-04 | 繰り返されました | Mizuho | Buy |
| 2016-10-24 | 繰り返されました | Wedbush | Neutral |
| 2016-10-10 | 繰り返されました | Mizuho | Buy |
| 2016-09-27 | 繰り返されました | WallachBeth | Hold |
すべてを表示
Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース
Ironwood Pharmaceuticals (IRWD) Faces Nasdaq Compliance Deadline - GuruFocus.com
Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice - Marketscreener.com
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire
Ironwood Pharma Gets 60-Day Window to Resolve Nasdaq Compliance Issue - StockTitan
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter
Irritable Bowel Syndrome Treatment Market Future Business - openPR
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Prev - GuruFocus.com
Analysts Say You Should Hold Your Position In Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) - Stocks Register
Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc. Class A to Host Earnings Call - accessnewswire.com
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down - MSN
Ironwood Pharma Delays 10-K Filing Due to Internal Issues - TipRanks
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? - Yahoo Finance
Los Angeles Capital Management LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results - MarketBeat
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Call Transcript - Insider Monkey
Ironwood: Q4 Earnings Snapshot - The Herald Review
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... By GuruFocus - Investing.com Canada
Ironwood Pharmaceuticals Reports 2024 Financial Results - TipRanks
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth - Investing.com India
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results - TradingView
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance - Business Wire
CIBC Asset Management Inc Takes $53,000 Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $8.60 - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call - BioSpace
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Growth in Short Interest - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD): A New Perspective - Stocks Register
FY2025 Earnings Forecast for IRWD Issued By Zacks Research - MarketBeat
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - MSN
Zacks Research Issues Negative Forecast for IRWD Earnings - MarketBeat
What is Zacks Research’s Estimate for IRWD FY2025 Earnings? - Defense World
Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD) 財務データ
収益
当期純利益
現金流量
EPS
Ironwood Pharmaceuticals Inc (IRWD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
| John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
| Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):